Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2017-04-20 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
PHARMENA_Projekty uchwał na ZWZ w dniu 30 05 2017
AGM Information Classification · 99% confidence The document text explicitly details the 'Projekty uchwał Zwyczajnego Walnego Zgromadzenia' (Draft resolutions of the Annual General Meeting) held on May 30, 2017. The resolutions cover the approval of management and financial reports for the period ending 2016, distribution of profit, and granting of 'absolutorium' (discharge/vote of confidence) to board and supervisory council members. These documents are the core content presented and voted upon during an AGM. Therefore, the classification should be AGM Information (AGM-R).
2017-04-20 Polish
PHARMENA_Ogłoszenie o zwołaniu ZWZ w dniu 30 05 2017
AGM Information Classification · 99% confidence The document is titled "Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Spółki..." which translates to "Announcement of the convening of the Ordinary General Meeting of the Company...". The text details the date, time, location, and a detailed agenda (Porządek obrad) for the meeting, including items related to approving annual reports and granting discharge (absolutorium). It also outlines procedures for shareholder participation, registration deadlines, and proxy voting rules. This content is characteristic of a formal notice calling for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2017-04-20 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia spółki Pharmena S.A. - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and announces the convening ('zwołaniu') of an Ordinary General Meeting ('Zwyczajnego Walnego Zgromadzenia') for PHARMENA S.A. on May 30, 2017. It explicitly states that the Management Board ('Zarząd Emitenta') is enclosing ('w załączeniu przekazuje') the announcement along with draft resolutions ('projektami uchwał'). Since this is an announcement about convening a general meeting and includes related materials (draft resolutions), it strongly aligns with the 'AGM Information' category, which covers presentations and materials shared during the Annual General Meeting (AGM). The short length (515 chars) and the nature of announcing the meeting details confirm this is not the full minutes or results, but the preparatory material/announcement for the AGM.
2017-04-20 Polish
Przekazanie do EFSA dodatkowej dokumentacji dot. wniosku o autoryzację 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A. regarding the submission of additional documentation to the European Food Safety Authority (EFSA) concerning the authorization of 1-MNA as a novel food ingredient. It references previous reports and discusses the potential impact on company revenue if authorization is granted. This type of communication, detailing regulatory progress on a key product/ingredient, is a general regulatory announcement. Since it does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or specific legal/capital events, the most appropriate classification is the general regulatory filing category.
2017-04-13 Polish
Zawarcie istotnej umowy na produkcję na rynki zagraniczne - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a short announcement (1217 characters) from the Management Board (Zarząd) of Pharmena S.A. It details the signing of a contract for manufacturing private label products for a pharmaceutical company in Bangladesh, outlining the target markets (Middle East, 49 global markets) and the strategic importance of this deal for sales expansion. This type of announcement, concerning a significant business agreement that is expected to impact future revenues, is typically classified as a general regulatory filing or a material event disclosure. Since it is not a specific financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is not explicitly about M&A (TAR) or capital changes (CAP/SHA), the most appropriate general category for a material business development announcement that doesn't fit elsewhere is Regulatory Filings (RNS). It is too specific for RNS if a better fit exists, but given the options, it describes a significant business transaction/contract signing. If this were a US filer, it might be an 8-K item, but among the provided Polish/European-style codes, RNS serves as the best catch-all for material, non-standard announcements.
2017-03-24 Polish
Przedłożenie dodatkowej dokumentacji dot. wniosku o autoryzację 1-MNA jako nowego składnika żywności - Content (PL)
Legal Proceedings Report Classification · 92% confidence The document discusses an ongoing regulatory process involving PHARMENA S.A. and the European Food Safety Authority (EFSA) regarding the authorization of '1-MNA' as a novel food ingredient. It details a request for additional documentation, the timeline for response, and the potential impact on the company's revenue if authorization is granted. This content relates to regulatory compliance, legal/administrative procedures concerning a product, and its potential market entry. It is not a standard financial report (10-K, IR, ER), a management change announcement (MANG), or a director's dealing (DIRS). Since it specifically concerns legal/regulatory action/updates regarding a product authorization process, it fits best under Legal Proceedings Report (LTR) or potentially Regulatory Filings (RNS) if LTR is too narrow. Given the focus on a specific regulatory request and the potential for market authorization (a legal/administrative hurdle), LTR is a strong candidate, but RNS is often used for general regulatory updates that aren't standard SEC forms or specific legal suits. However, the content is highly specific to a regulatory/administrative hurdle for a product, which often falls under LTR in broader classification schemes when dealing with non-SEC filings, or RNS as a general regulatory update. Since the text describes a specific administrative request from a regulatory body (EFSA) concerning product approval, and it is not a standard financial report, RNS (Regulatory Filings - general fallback) is the most appropriate general category for non-standard regulatory correspondence updates, especially since it doesn't detail a lawsuit (LTR). The document is an update on a regulatory process, not a formal legal proceeding or a standard financial disclosure.
2017-03-23 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.